ArticleClinical drug investigation2025

Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy Compared with Chemotherapy as First-Line Treatment for Advanced PD-L1-Positive Triple-Negative Breast Cancer from a Japanese Healthcare Perspective.

Yugo Chisaki et al.PubMed ↗Publisher ↗

No numbers read from the abstract.